Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism
Standard
Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism. / Nowak-Göttl, U; Koch, H G; Aschka, I; Kohlhase, B; Vielhaber, H; Kurlemann, G; Oleszcuk-Raschke, K; Kehl, H G; Jürgens, H; Schneppenheim, R.
In: BRIT J HAEMATOL, Vol. 92, No. 4, 03.1996, p. 992-8.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism
AU - Nowak-Göttl, U
AU - Koch, H G
AU - Aschka, I
AU - Kohlhase, B
AU - Vielhaber, H
AU - Kurlemann, G
AU - Oleszcuk-Raschke, K
AU - Kehl, H G
AU - Jürgens, H
AU - Schneppenheim, R
PY - 1996/3
Y1 - 1996/3
N2 - Resistance to activated protein C (APCR), in the majority of cases due to the point mutation Arg 506 Gln of the factor V gene, has emerged as the most important hereditary cause of venous thromboembolism. Using an activated thromboplastin time (aPTT) based method in the presence of APC together with a DNA technique based on the polymerase chain reaction, we investigated 37 children with venous (V: n=19) or arterial (A: n=18) thromboembolism and 196 age-matched healthy controls for the presence of this mutation. In the control group 10 children were detected to be heterozygous for the factor V Leiden mutation, indicating a prevalence of 5.1%. 10/19 children (52%) with venous thrombosis and 7/18 (38%) patients with arterial thromboembolism showed the common factor V gene mutation. Additional inherited coagulation disorders were found in 1/10 (V:10%) and 2/7 (A:28%) APC-resistant patients. Inherited coagulation disorders without APCR were diagnosed in 3/9 (V: 33%) and 2/11 (A:18%) children. Furthermore, we diagnosed exogenous risk factors in 6/10 (V: 60%) and 2/7 (A: 28%) children with thrombosis and APCR. These data are evidence that APCR combined with exogenous reasons may play an important role in the early manifestation of thromboembolism during infancy and childhood.
AB - Resistance to activated protein C (APCR), in the majority of cases due to the point mutation Arg 506 Gln of the factor V gene, has emerged as the most important hereditary cause of venous thromboembolism. Using an activated thromboplastin time (aPTT) based method in the presence of APC together with a DNA technique based on the polymerase chain reaction, we investigated 37 children with venous (V: n=19) or arterial (A: n=18) thromboembolism and 196 age-matched healthy controls for the presence of this mutation. In the control group 10 children were detected to be heterozygous for the factor V Leiden mutation, indicating a prevalence of 5.1%. 10/19 children (52%) with venous thrombosis and 7/18 (38%) patients with arterial thromboembolism showed the common factor V gene mutation. Additional inherited coagulation disorders were found in 1/10 (V:10%) and 2/7 (A:28%) APC-resistant patients. Inherited coagulation disorders without APCR were diagnosed in 3/9 (V: 33%) and 2/11 (A:18%) children. Furthermore, we diagnosed exogenous risk factors in 6/10 (V: 60%) and 2/7 (A: 28%) children with thrombosis and APCR. These data are evidence that APCR combined with exogenous reasons may play an important role in the early manifestation of thromboembolism during infancy and childhood.
KW - Adolescent
KW - Blood Protein Disorders
KW - Child
KW - Child, Preschool
KW - Female
KW - Humans
KW - Infant
KW - Infant, Newborn
KW - Intracranial Embolism and Thrombosis
KW - Magnetic Resonance Angiography
KW - Male
KW - Prospective Studies
KW - Protein C
KW - Thromboembolism
KW - Tomography, X-Ray Computed
M3 - SCORING: Journal article
C2 - 8616099
VL - 92
SP - 992
EP - 998
JO - BRIT J HAEMATOL
JF - BRIT J HAEMATOL
SN - 0007-1048
IS - 4
ER -
